The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
May 19th 2024
With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clyde Yancy, MD: The Prospect of Renal Denervation for Hypertension
March 6th 2023At ACC 2023, HCPLive editorial team sat down with Clyde Yancy, MD, to learn more about his perspective on recent and upcoming advances in cardiovascular care. In this interview, Yancy discusses his perspective on the clinical trial data surrounding renal denervation as a treatment for hypertension.
Linking Flu Vaccine to Cardiovascular Benefit Could Increase Uptake in Older Adults
March 5th 2023In the largest implementation trial ever conducted, new research from the NUDGE FLU trial suggests informing patients of the potential cardiovascular benefits associated with receipt of the flu vaccine could increase uptake among older adults.
Immediate Complete Revascularization Non-Inferior to Staged Procedure in BIOVASC Trial
March 5th 2023In patients with acute coronary syndrome and multi-vessel heart disease, immediate stent treatment was as safe and effective as staged treatment at one year, according to late-breaking data presented at ACC 2023.
How Patients Benefit from Growing Intersectionality of Renal and Cardiovascular Diseases
March 4th 2023At ACC.23, our editorial team sat down with a pair of leaders in cardiometabolic health to get their perspective on the growing intersectionality of cardiovascular and chronic kidney disease and how patients have been the beneficiaries of this growing recognition.
Transcatheter Repair Benefits Quality of Life in Patients with Severe Tricuspid Regurgitation
March 4th 2023The TRILUMINATE Pivotal trial reports a reduction in the severity of tricuspid regurgitation with TEER, but no significant difference in survival or hospitalization after one year of follow-up.
Bempedoic Acid Reduces Risk of MACE by 13%, But Proves No Benefit on Cardiovascular Death
March 4th 2023Results of the CLEAR Outcomes trial suggests adherence to bempedoic acid was associated with a 13% relative reduction in incidence of the trial's primary endpoint of 4-point MACE, but no benefit was observed for risk of cardiovascular death or all-cause mortality in the trial.
COVID-19 Vaccination Can Reduce Cardiovascular Risk Post-Infection, Study Finds
February 20th 2023Using data from nearly 2 million US patients with a documented COVID-19 infection, a new study provides an overview of the impact of vaccination, both full and partial, on risk of MACE following infection.
In Type 2 Diabetes, Low Carb Diet Linked to Lower Risk of Death from Cancer, Cardiovascular Disease
February 16th 2023Using data from a pair of major studies, investigators from the Harvard T.H. Chan School of Public Health shed new light on the impact of low-carbohydrate diet scores in people with type 2 diabetes.
Go Red for Women Day: Confronting Glass Ceilings in Medicine
February 3rd 2023In recognition of Go Red for Women Day on February 3, this feature shines a spotlight on the hurdles faced by women in cardiology and offers perspective on the battle for gender-based equity in medicine from the perspective of a pair of female leaders.
Abbott Announces Regulatory Decisions for a Pair of Arrhythmia Devices
February 2nd 2023On February 2, Abbott announced their FlexAbility™ Ablation Catheter, Sensor Enabled had received an expanded approval from the US Food and Drug Administration and their TactiFlex™ Ablation Catheter, Sensor Enabled received a CE Mark.
Gluconic Acid Could Serve as Race-Specific Biomarker for Hypertension and Stroke Risk
February 2nd 2023A study presented at the International Stroke Conference 2023 suggests the plasma metabolite gluconic acid could serve as a race-specific biomarker for identifying increased risk of hypertension and stroke in Black adults.
Patients with Celiac Disease Had Higher CVD Risk, Despite Lower Risk Factor Prevalence
January 31st 2023An analysis of the UK Biobank suggests individuals with celiac disease had an incidence rate of 9.0 CVD cases per 1000 person years compared with 7.4 per 1000 person years in people with no celiac disease.